SLC-0111 is under clinical development by SignalChem Lifesciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SLC-0111’s likelihood of approval (LoA) and phase transition for Pancreatic Ductal Adenocarcinoma took place on 24 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SLC-0111 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SLC-0111 overview

SLC-0111 is under development for the treatment of metastatic pancreatic ductal adenocarcinoma. It is administered through oral route. The drug candidate acts by targeting carbonic anhydrase IX and developed based on the KineCore technology. It was also under development for the treatment of solid tumors, breast cancer and recurrent glioblastoma multiforme (GBM).

SignalChem Lifesciences overview

SignalChem Lifesciences (SLC) is a biotechnology company that discovers and develops novel therapies for oncology. The company is investigating SLC-391, an orally bioavailable small molecule AXL inhibitors to treat acute myelogenous leukemia and non-small cell lung cancer; and SLC-0111, a carbonic anhydrase IX (CAIX) Inhibitor targeting pancreatic cancer. It is also evaluating additional programs targeting cancer and SARS-CoV-2 (corona virus). SLC provides drug discovery, in-vitro diagnostic development, research and development solutions. The company works in collaboration with pharmaceutical and biopharmaceutical companies to develop its products. SLC is headquartered in Richmond, British Columbia, Canada.

Quick View SLC-0111 LOA Data

Report Segments
  • Innovator
Drug Name
  • SLC-0111
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.